China Approves Two More Home-Grown COVID-19 Antivirals

 
• By Dexter Jie Yan

Top-line results for two newly approved COVID-19 antivirals in China showed roughly 1.5- to two-day cuts in median time to symptom resolution or recovery in mild-to-moderate Omicron patients versus placebo.

endpoint of symptom resolution
time to symptom resolution or recovery a top pick for primary endpoint in COVID antiviral trials • Source: Shutterstock

More from China

More from Asia